GlaxoSmithKline, the UK-based pharmaceutical company, is unlikely to receive US approval for its key cervical cancer vaccine until 2010 at the earliest, under a new timetable it released on Monday. After requests for fresh information on Cervarix from the Food & Drug Administration in December, GSK said it had decided to await completion of a pivotal clinical trial to be filed with the US regulator during the first half of next year.
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/news/gsk-faces-us-delay-cancer-vaccine
[2] http://admin.indiaenvironmentportal.org.in/category/author/andrew-jack
[3] http://admin.indiaenvironmentportal.org.in/category/newspaper/financial-times-london
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/cancer
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drug-industry
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/vaccination
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/united-kingdom-uk
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/united-states-america-us
